Please login to the form below

Not currently logged in
Email:
Password:

HCC

This page shows the latest HCC news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo defies naysayers with healthy growth

BMS’ Opdivo defies naysayers with healthy growth

We are also looking forward to seeing data for Opdivo in first-line HCC and for the combination in head and neck and small cell lung cancer next year, ”said

Latest news

  • Ipsen’s liver cancer treatment clears phase III trial Ipsen’s liver cancer treatment clears phase III trial

    results. The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients with advanced hepatocellular carcinoma (HCC), the sixth most common form of cancer with around 800, ... Ipsen will now “evaluate potential next steps in

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Bayer's Nexavar backed by NICE for liver cancer. The drug is the only approved first-line treatment for advanced HCC. ... the hope to also provide the first approved second-line treatment option for patients with HCC, who have previously been treated

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    EMA clears Bayer's Stivarga for liver cancer. The multikinase inhibitor will treat patients with HCC. ... Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the US for patients with HCC,"

  • FDA OK for Stivarga ends decade-long drought in liver cancer FDA OK for Stivarga ends decade-long drought in liver cancer

    Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular carcinoma (HCC) who have been previously treated with Bayer's older drug Nexavar (sorafenib). ... This is the first time patients with

  • Bayer nets speedy US review for regorafenib in liver cancer Bayer nets speedy US review for regorafenib in liver cancer

    Bayer nets speedy US review for regorafenib in liver cancer. Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales. ... The FDA is reviewing the drug for the second-line treatment of patients with a form of liver

More from news
Approximately 3 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Mining for results Mining for results

    The first product to come from Apixio's technology platform is called the HCC Profiler.

  • Pharma Perspectives: The agency selection process (part 2) Pharma Perspectives: The agency selection process (part 2)

    Samuel Hollis is a business unit director at AstraZeneca. In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist

  • Pharma Perspectives: The agency selection process (part 1) Pharma Perspectives: The agency selection process (part 1)

    In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of Communications

  • Pharma perspectives: communications creativity (part 2) Pharma perspectives: communications creativity (part 2)

    In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of

  • Pharma perspectives: communications creativity (part 1) Pharma perspectives: communications creativity (part 1)

    In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics